A Forward Look, the Year Ahead - Featured Research on Alnylam Pharmaceuticals, Inc. and ISIS Pharmaceuticals, Inc.
(firmenpresse) - HONG KONG -- (Marketwire) -- 02/17/12 -- Today, introduced featured coverage of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS). Full research reports are available to readers at: .
Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.
Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.
Bollinger Report screened and selected Alnylam Pharmaceuticals, Inc. for its current position within the healthcare industry. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). The RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. A copy of this report featuring Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is available at: .
Bollinger Report is featuring ISIS Pharmaceuticals, Inc. for its changing role within the healthcare industry. Isis Pharmaceuticals, Inc. (Isis) is engaged in antisense technology, exploiting a drug discovery platform to create a pipeline of drugs. The Company operates in two business segments: Drug Discovery and Development and Regulus Therapeutics Inc. To download researches and analysis on ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) we welcome investors to visit: .
About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.
Contact:
Martin Schwartz
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.02.2012 - 08:00 Uhr
Sprache: Deutsch
News-ID 1084332
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
HONG KONG
Phone:
Kategorie:
Investment Services & Trading
Anmerkungen:
Diese Pressemitteilung wurde bisher 66 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"A Forward Look, the Year Ahead - Featured Research on Alnylam Pharmaceuticals, Inc. and ISIS Pharmaceuticals, Inc.
"
steht unter der journalistisch-redaktionellen Verantwortung von
Bollinger Report (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
